| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c442999bbcba48bd4cea2780d2d013a4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 |
| filingDate |
2008-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09afe15f5b143d145d87608e037a8409 |
| publicationDate |
2008-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008260701-A1 |
| titleOfInvention |
Anti-angiogenic cellular agent for cancer therapy |
| abstract |
The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10772914-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011182870-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11118164-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102625832-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011028531-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9963677-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10821134-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10385316-B2 |
| priorityDate |
1999-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |